AMA to help doctors cash in on EHR stimulus dollars

Share this article:
Doctors that demonstrate the “meaningful use” of electronic health records (EHR) in their practices are eligible for at least $44,000 over five years, an incentive the American Medical Association (AMA) is facilitating with a new partnership.

AMA's partnership with UnitedHealth-owned Ingenix will offer physicians a way to “assess and meet their clinical and practice needs,” as well as “access information, products and services with a single, secure sign-on,” according to an AMA release.

The platform is currently in beta testing through a collaboration with the Michigan State Medical Society, and will launch nationwide later this year, according to the release.

The Ingenix CareTracker platform will also help physicians demonstrate meaningful use of an EHR system, the key qualification for payment under the American Reinvestment and Recovery Act, said Bill Miller, EVP, healthcare delivery systems at Ingenix in the release.

A survey conducted by online physician community Sermo and AthenaHealth, an EHR provider, found that 80% of responding Sermo docs view EHRs favorably, believing that they improve patient care.

However, 90% of the docs surveyed said they agree or strongly agree that EHRs are expensive to purchase, and 60% agree or strongly agree that EHRs “distract from face to face interaction with patients,” according to survey results.

“Discussion amongst the Sermo physician community supports the survey's findings of ‘holes' in current offerings and more broadly the notion that EHRs have a long way to go towards delivering on the promise of cost savings, freed resources, and better medicine,” said Daniel Palestrant, Sermo CEO, in a statement.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.